Carmichael Hill & Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Carmichael Hill & Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.1K	Hold	82	–	–	﹤0.01%	613
2024 Q2	$7.6K	Hold	82	–	–	﹤0.01%	598
2024 Q1	$7.78K	Buy	82 +51	+165%	+$4.73K	﹤0.01%	591
2023 Q4	$2.77K	Hold	31	–	–	﹤0.01%	689
2023 Q3	$2.26K	Hold	31	–	–	﹤0.01%	694
2023 Q2	$2.58K	Hold	31	–	–	﹤0.01%	687
2023 Q1	$2.36K	Hold	31	–	–	﹤0.01%	689
2022 Q4	$2.57K	Sell	31 -534	-95%	-$43.2K	﹤0.01%	673
2022 Q3	$45K	Buy	565 +145	+35%	+$12.2K	0.02%	344
2022 Q2	$31K	Sell	420 -200	-32%	-$15K	0.02%	406
2022 Q1	$56K	Buy	620 +298	+93%	+$27.5K	0.03%	338
2021 Q4	$36K	Hold	322	–	–	0.02%	427
2021 Q3	$40K	Sell	322 -49	-13%	-$6.31K	0.02%	401
2021 Q2	$50K	Hold	371	–	–	0.03%	353
2021 Q1	$50K	Hold	371	–	–	0.03%	339
2020 Q4	$52K	Hold	371	–	–	0.03%	313
2020 Q3	$41K	Sell	371 -10	-3%	-$1.12K	0.03%	322
2020 Q2	$43K	Buy	381 +216	+131%	+$21.3K	0.03%	296
2020 Q1	$13K	Buy	165 +40	+32%	+$3.54K	0.01%	435
2019 Q4	$12K	Buy	+125	New	+$10.8K	0.01%	469

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Carmichael Hill & Associates's XBI Position: Q3 2024 in Review

Carmichael Hill & Associates held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2024 at 82 shares worth $8.1K. The position accounts for ﹤0.01% of the portfolio, ranked #613.

Carmichael Hill & Associates first reported a position in XBI in Q4 2019 and has held it in 20 quarters since. The position peaked at $56K in Q1 2022. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Carmichael Hill & Associates held 82 shares of State Street SPDR S&P Biotech ETF worth $8.1K as of Q3 2024.
Carmichael Hill & Associates left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2024.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #613 holding.
Carmichael Hill & Associates first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 20 quarters since.
Carmichael Hill & Associates's State Street SPDR S&P Biotech ETF position peaked at $56K in Q1 2022.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.